Search details
1.
mRNA: A Novel Avenue to Antibody Therapy?
Mol Ther
; 27(4): 773-784, 2019 04 10.
Article
in English
| MEDLINE | ID: mdl-30885573
2.
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
Cancer Immunol Immunother
; 68(5): 799-812, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30770959
3.
A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects.
J Immunol
; 198(4): 1595-1605, 2017 02 15.
Article
in English
| MEDLINE | ID: mdl-28077601
4.
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
Lancet
; 390(10101): 1511-1520, 2017 Sep 23.
Article
in English
| MEDLINE | ID: mdl-28754494
5.
Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model.
Cancer Immunol Immunother
; 67(4): 653-662, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29335856
6.
Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response.
J Transl Med
; 15(1): 1, 2017 01 03.
Article
in English
| MEDLINE | ID: mdl-28049494
7.
Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.
Mol Ther
; 23(9): 1456-64, 2015 Sep.
Article
in English
| MEDLINE | ID: mdl-26050989
8.
A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.
Int J Cancer
; 137(2): 372-84, 2015 Jul 15.
Article
in English
| MEDLINE | ID: mdl-25530186
9.
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
BMC Cancer
; 14: 748, 2014 Oct 06.
Article
in English
| MEDLINE | ID: mdl-25288198
10.
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.
J Gene Med
; 14(6): 428-39, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22262664
11.
Developing mRNA-vaccine technologies.
RNA Biol
; 9(11): 1319-30, 2012 Nov.
Article
in English
| MEDLINE | ID: mdl-23064118
12.
Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway.
RNA Biol
; 8(4): 627-36, 2011.
Article
in English
| MEDLINE | ID: mdl-21654214
13.
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.
NPJ Vaccines
; 6(1): 57, 2021 Apr 16.
Article
in English
| MEDLINE | ID: mdl-33863911
14.
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Wien Klin Wochenschr
; 133(17-18): 931-941, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34378087
15.
RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.
Vaccine
; 37(13): 1819-1826, 2019 03 22.
Article
in English
| MEDLINE | ID: mdl-30797640
16.
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
J Immunother Cancer
; 7(1): 38, 2019 02 08.
Article
in English
| MEDLINE | ID: mdl-30736848
17.
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.
NPJ Vaccines
; 2: 29, 2017.
Article
in English
| MEDLINE | ID: mdl-29263884
18.
mRNA mediates passive vaccination against infectious agents, toxins, and tumors.
EMBO Mol Med
; 9(10): 1434-1447, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28794134
19.
Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity.
Vaccine
; 34(33): 3882-93, 2016 07 19.
Article
in English
| MEDLINE | ID: mdl-27269061
20.
Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.
Oncoimmunology
; 5(12): e1249560, 2016.
Article
in English
| MEDLINE | ID: mdl-28123889